Here, we used the US Department of Veterans Affairs databases to build a cohort of people with diabetes who initiated GLP-1RA ( n = 215,970) and compared them to those who initiated sulfonylureas ( n = 159,465), dipeptidyl peptidase 4 (DPP4) inhibitors ( n = 117,989) or sodiumglucose cotransporter-2 (SGLT2) inhibitors ( n = 258,614), a control group composed of an equal proportion of individuals initiating sulfonylureas, DPP4 inhibitors and SGLT2 inhibitors ( n = 536,068), and a control group of 1,203,097 individuals who continued use of non-GLP-1RA antihyperglycemics (usual care)
But there will come a day when we no longer see these access barriers for GLP-1s. Healthcare Helpline helps you navigate the health system hurdles between you and good care
Sokos GG, Bolukoglu H, German J, Hentosz T, Magovern GJ, Maher TD, Dean DA, Bailey SH, Marrone G, Benckart DH, Elahi D, Shannon RP: Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting
Discontinue Byetta if pancreatitis is suspected Notes: The discovery of DPP-IV-resitant GLP-1 analogs was pursued in parallel with the discovery of DPP-IV inhibitors
However, an unphysiologically large postprandial release of GLP1, for example, after gastric bypass surgery (Korner et al., 2007), might reach the circumventricular organs, and DPP4resistant GLP1 receptor agonists clearly have central actions, though whether this includes action on GLP1 receptors inside the BBB or is limited to direct activation of GLP1 receptors in the circumventricular organs outside the BBB, is less clear (Adams et al., 2018
.png.jpg)
